Last 1,191 GBp
Change Today -9.00 / -0.75%
Volume 2.9M
SN/ On Other Exchanges
Symbol
Exchange
London
New York
OTC US
Frankfurt
Frankfurt
As of 11:35 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

smith & nephew plc (SN/) Snapshot

Open
1,201 GBp
Previous Close
1,200 GBp
Day High
1,206 GBp
Day Low
1,191 GBp
52 Week High
01/9/15 - 1,211 GBp
52 Week Low
04/16/14 - 858.50 GBp
Market Cap
10.6B
Average Volume 10 Days
2.5M
EPS TTM
0.56 GBp
Shares Outstanding
894.0M
EX-Date
10/23/14
P/E TM
31.9x
Dividend
0.28 GBp
Dividend Yield
1.58%
Current Stock Chart for SMITH & NEPHEW PLC (SN/)

Related News

No related news articles were found.

smith & nephew plc (SN/) Related Businessweek News

No Related Businessweek News Found

smith & nephew plc (SN/) Details

Smith & Nephew plc develops, manufactures, markets, and sells medical devices in the advanced surgical devices and advanced wound management sectors worldwide. The company’s Advanced Surgical Devices segment offers orthopaedic reconstruction implants for hip, knee, and shoulder joints; and ancillary products, such as bone cement and mixing systems used in cemented reconstruction joint surgery. It also provides sports medicine products, which offer surgeons an array of instruments, technologies, and implants to perform minimally invasive surgery of the joints, including knee, hip, and shoulder repair; and trauma and extremities products consisting of internal and external devices and other products, including shoulder fixation and orthobiological materials used in the stabilization of fractures and deformity correction procedures. In addition, this segment provides arthroscopy enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, as well as offers radio frequency wands, electromechanical and mechanical blades, and hand instruments for removing damaged tissues to healthcare providers. The company’s Advanced Wound Management segment offers a range of initial wound bed preparation and full wound closure products. Its products are targeted at chronic wounds associated with the older population, such as pressure sores and venous leg ulcers; and products for the treatment of wounds, such as burns and invasive surgery. Smith & Nephew plc primarily serves medical and surgical treatments and service providers. The company was founded in 1856 and is headquartered in London, the United Kingdom.

14,000 Employees
Last Reported Date: 10/30/14
Founded in 1856

smith & nephew plc (SN/) Top Compensated Officers

Chief Executive Officer, Director, Chairman o...
Total Annual Compensation: $4.2M
Chief Financial Officer, Director and Member ...
Total Annual Compensation: $2.0M
Compensation as of Fiscal Year 2013.

smith & nephew plc (SN/) Key Developments

Smith & Nephew Denies Sales Rumors

Smith & Nephew plc (LSE:SN.) does not intend to sell its wound care unit to Coloplast A/S (CPSE:COLO B), Olivier Bohoun, Chief Executive Officer of Smith & Nephew told financial and corporate intelligence provider Mergermarket. Bohoun denied rumors it could sell the business to Coloplast, speaking on the sidelines at the JPMorgan Healthcare conference in San Francisco on January 12, 2015.

Smith & Nephew plc Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 03:00 PM

Smith & Nephew plc Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 03:00 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Olivier Bohuon, Chief Executive Officer, Director, Chairman of Disclosures Committee, Chairman of Executive Risk Committee, Member of Nomination & Governance Committee and Member of Nomination & Governance Committee.

Stryker Reportedly Plans Offer For Smith & Nephew

Stryker Corporation (NYSE:SYK) is planning a takeover offer for Smith & Nephew plc (LSE:SN.), according to people with knowledge of the matter. Stryker plans to offer a significant premium to Smith & Nephew’s current share price, with one of the people saying it could be about 30%. Stryker is not planning a tax inversion because of the limited tax benefits and political risk, said one of the people, who asked not to be identified because deliberations are private, reported Bloomberg. The bid is still being finalized and the timing could change, said the people. There’s also a chance that Stryker may decide against an offer, one of the people said. Representatives for Stryker and Smith & Nephew declined to comment, reported Bloomberg.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SN/:LN 1,191.00 GBp -9.00

SN/ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Coloplast A/S kr520.50 DKK -4.00
CR Bard Inc $171.03 USD -5.91
Edwards Lifesciences Corp $125.35 USD -3.93
Olympus Corp ¥4,120 JPY -15.00
St Jude Medical Inc $65.87 USD -0.47
View Industry Companies
 

Industry Analysis

SN/

Industry Average

Valuation SN/ Industry Range
Price/Earnings 32.1x
Price/Sales 3.5x
Price/Book 4.0x
Price/Cash Flow 31.9x
TEV/Sales 3.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SMITH & NEPHEW PLC, please visit www.smith-nephew.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.